Background:Otilimab is an IgG1 mAb that binds to GM-CSF and hinders its interaction with GM-CSFRα; it was developed by Morphosys AG MOR-103 and then sublicensed to GSK GSK3196165 to conduct large-scale clinical trials.
Alternative Names:MOR-04357, 3196165, GSK3196165, MOR103,